'US sales of Truxima imminent'
Celltrion Chairman Seo Jung-jin said Wednesday that U.S. sales for Truxima, a Rituxan biosimilar which received approval from the U.S. Food and Drug Administration last year, is imminent. Celltrion Chairman Seo Jung-jin explains the company’s current position in the U.S. market and its g
Samsung BioLogics, Eutilex to develop anti-cancer immunotherapies
Samsung BioLogics said Wednesday that it has signed a contract development organization (CDO) agreement with Eutilex to cooperate on developing anti-cancer immunotherapies. Samsung BioLogics CEO Kim Tae-han (right) and Eutilex CEO Kwon Byeong-se shake hands after signing a CDO agreement
Helicobacter pylori in stomach increase risk of metabolic syndrome
Researchers at Seoul National University Bundang Hospital have discovered that Helicobacter pylori (H. pylori), a bacterium in the gastrointestinal mucosa, can increase the risk of metabolic syndrome. Professors Kim Na-young (left) and Im Sun-hee of Seoul National University Bundang Hosp
Medytox launches 3rd BTX product
Medytox said Wednesday that it has launched Coretox, a pure botulinum toxin (BTX) product which lowered the risk of resistance by removing non-toxic protein. Medytox‘s 3rd BTX product Coretox Coretox is the company’s third BTX formulation in Korea, following Medytoxin, the first locall